Progressive Supranuclear Palsy News and Research

RSS

New treatments in sight for challenging neuropsychiatric symptoms in neurodegenerative diseases

Study reviews the advancements in pharmacological treatments for neuropsychiatric syndromes in neurodegenerative disorders, discussing the complexities of managing symptoms such as depression, disinhibition, apathy, psychosis, and agitation to improve patient care.

3 Apr 2024

Innovative approach to disrupt misfolding of tau proteins in neurodegenerative diseases

A spectrum of neurodegenerative diseases, including frontotemporal dementia (FTD), progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) are due to the accumulation of abnormal, misfolded tau proteins in the brain.

3 Apr 2024

C-Path announces formation of new task force to foster drug development for Progressive Supranuclear Palsy

Critical Path Institute (C-Path) today announced the formation of a new task force under its Rare Disease Cures Accelerator-Data and Analytics Platform, dedicated to advancing therapeutic development for Progressive Supranuclear Palsy.

26 Mar 2024

UVA Alzheimer's study pinpoints how tau protein damages brain cells

University of Virginia Alzheimer's researchers have discovered how harmful tau proteins damage the essential operating instructions for our brain cells, a finding which could lead to new treatments.

20 Dec 2023

Redefining the battle against Alzheimer's with tau-focused treatments

Researchers explore the potential of tau-targeting therapies in treating Alzheimer's disease, focusing on immunotherapies and strategies to improve their efficacy. The study dives into the complex biology of tau proteins, their modifications, and how they can be targeted to halt the progression of Alzheimer's.

29 Oct 2023

Wearable devices and machine learning revolutionize Parkinson's disease monitoring

The quantitative progression of motor symptoms of Parkinson's disease (PD) over time using wearable sensor data.

11 Oct 2023

New tau PET radiotracer shows promise for early detection of Alzheimer's disease

A new tau PET radiotracer, 18F-SNFT-1, has been found to be more effective than existing tau PET radiotracers in identifying Alzheimer's disease in its earliest stages, according to research published in the September issue of The Journal of Nuclear Medicine.

29 Sep 2023

Decoding tauopathies: New study identifies non-coding RNA as a key player in Alzheimer's

Researchers at Washington University School of Medicine identify a key step in the development of harmful tau tangles, offering a potential target for preventing brain damage in diseases like Alzheimer's. The study highlights the role of long noncoding RNAs, particularly SNHG8, in stress granule formation and tau aggregation, opening new avenues for treatment.

22 Sep 2023

Penn Medicine researchers identify new therapeutic target for Alzheimer's disease

A gene encoding a protein linked to tau production-;tripartite motif protein 11 (TRIM11)-;was found to suppress deterioration in small animal models of neurodegenerative diseases similar to Alzheimer's disease (AD), while improving cognitive and motor abilities, according to new research from the Perelman School of Medicine at the University of Pennsylvania.

27 Jul 2023

Researchers explore multi-syndrome prediction of dementia syndromes

A new study explored how support vector machines (SVMs) applied to magnetic resonance imaging (MRI) data can differentiate different dementia syndromes.

16 Jan 2023

Targeting defective tau proteins may be needed to treat Alzheimer’s patients

In November, researchers reported the drug lecanemab slowed the progression of Alzheimer's disease. The effect was modest, but it has generated tremendous excitement because it was the first time a drug had been shown to be able to affect the course of this relentless, incurable disease.

26 Dec 2022

Possibility of the first fluid biomarker that reflects brain pathology in primary tauopathies

Addressing this gap in research, a recent Nature Medicine study hypothesized that 4R isoform-specific MTBR-tau species accumulate in the patient’s brain of specific subtypes of 4R tauopathies.

28 Nov 2022

New biomarker can help identify people with a primary tauopathy

Zooming in on a single disease and studying it intensely is often the most productive route to finding treatments. But there's no easy way to distinguish among people living with any of the primary tauopathies -; a group of rare brain diseases marked by rapidly worsening problems with thinking and movement -; because the symptoms are too similar.

24 Nov 2022

Combination of new testing methods helps identify multiple dementia risk genes

A new UCLA-led study has identified multiple new risk genes for Alzheimer's disease and a rare, related brain disorder called progressive supranuclear palsy (PSP) by using a combination of new testing methods allowing for mass screening of genetic variants in a single experiment.

18 Aug 2022

New center aims to accelerate research into biomarkers of neurodegenerative diseases

A new center established at Washington University School of Medicine in St. Louis aims to accelerate research into biomarkers of neurodegenerative conditions such as Huntington's and Parkinson's diseases, amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS) and the so-called tauopathies, a group that includes Alzheimer's disease along with rarer diseases such as frontotemporal dementia, corticobasal syndrome and progressive supranuclear palsy.

13 Jul 2022

Ultra-high strength 7T MRI scanner offers hope for treating cognitive symptoms in Parkinson’s patients

Ultra-powerful 7T MRI scanners could be used to help identify those patients with Parkinson's disease and similar conditions most likely to benefit from new treatments for previously-untreatable symptoms, say scientists.

17 May 2022

New deep learning method aids in the accurate diagnosis of parkinsonian diseases

A new deep learning method has been created to aid in the diagnosis of parkinsonian diseases, according to research published ahead of print by The Journal of Nuclear Medicine.

21 Apr 2022

Inhibiting key signaling pathway in immune cells may slow down Alzheimer's disease

Inhibiting an important signaling pathway in brain-resident immune cells may calm brain inflammation and thereby slow the disease process in Alzheimer's and some other neurodegenerative diseases, suggests a study by Weill Cornell Medicine investigators.

14 Apr 2022

Study: Targeting astrocytes reduces tau-related brain damage and inflammation in mice

Alzheimer's disease is the most common and best known of the tauopathies, a set of neurodegenerative brain diseases caused by toxic tangles of the protein tau.

18 Mar 2022

Skin biopsy can aid in early identification and differential diagnosis of Parkinson's disease

The diagnosis of Parkinson's disease (PD) is currently based on consensus clinical criteria. A novel study reported in the Journal of Parkinson's Disease has found that the presence of neuronal deposits of the biomarker phosphorylated alpha-synuclein (p-syn) in the brain and the skin of patients with PD distinguishes them from individuals with symptoms of parkinsonism due to the accumulation of another protein, tau.

15 Mar 2022